Roche and AREVA Med, a subsidiary of AREVA, announced that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need. Under this exclusive agreement, Roche's Pharma Research and Early Development, or pRED, organization and AREVA Med will assess the efficacy of combining Roche-engineered antibodies with AREVA Med's radionuclide, Lead-212, a compound that shows promise in treating some types of cancer. Roche retains exclusive rights to commercialise the cancer radio-immunotherapy after clinical development. The alliance combines Roche's expertise in engineered antibodies with AREVA Med's proficiency in developing radioactive isotopes.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?